Cited by 1,012Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and SignalingNerve injury and regeneration

The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.

Clinical progression in Parkinson disease and the neurobiology of axons

Open access

Cheng, Hsiao‐Chun, Ulane, Christina M., Burke, Robert E.·2010·Annals of Neurology

DOI 10.1002/ana.21995PMC PMC2918373

Open this paper in CoChat — free account

Abstract

Despite tremendous growth in recent years in our knowledge of the molecular basis of Parkinson disease (PD) and the molecular pathways of cell injury and death, we remain without therapies that forestall disease progression. Although there are many possible explanations for this lack of success, one is that experimental therapeutics to date have not adequately focused on an important component of the disease process, that of axon degeneration. It remains unknown what neuronal compartment, either the soma or the axon, is involved at disease onset, although some have proposed that it is the axons and their terminals that take the initial brunt of injury. Nevertheless, this concept has not been formally incorporated into many of the current theories of disease pathogenesis, and it has not achieved a wide consensus. More importantly, in view of growing evidence that the molecular mechanisms of axon degeneration are separate and distinct from the canonical pathways of programmed cell death that mediate soma destruction, the possibility of early involvement of axons in PD has not been adequately emphasized as a rationale to explore the neurobiology of axons for novel therapeutic targets. We propose that ongoing degeneration of axons, not cell bodies, is the primary determinant of clinically apparent progression of disease, and that future experimental therapeutics intended to forestall disease progression will benefit from a new focus on the distinct mechanisms of axon degeneration.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/ana.21995

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

RETRACTED ARTICLE: APP binds DR6 to trigger axon pruning and neuron death via distinct caspases
Nikolaev, A., McLaughlin, T., O’Leary, D. D. M., & Tessier-Lavigne, M. (2009) · Nature · doi:10.1038/nature07767 · Cited by 992
Retracted
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 1×
“It has been proposed that PD begins in the regions of the dorsal motor nucleus of the vagus and the olfactory bulb.(14) However, this proposal has been controversial and does not relate directly to the question of the initial events at the cellular level.”
Background
α-Synuclein in Lewy bodies
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382 · cited 4×
“The impact was further amplified when it was discovered that -synuclein protein is a major component of LB.36 With the development of sensitive antibodies to -synuclein, it has become easier to detect LB in tissue sections, and they have become a great focus of attention.”
BackgroundInfluential
Parkinson's Disease
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
Brain dopamine and the syndromes of Parkinson and Huntington Clinical, morphological and neurochemical correlations
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K. A., & SEITELBERGER, F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90175-5 · Cited by 2,650 · cited 2×
“(A) A graphical representation of the data presented in the oft-cited Bernheimer et al study to support the statement that there is an 80% reduction at the time of disease onset.(26) In the Bernheimer study, only 13 brains from patients with a diagnosis of Parkinson disease (PD) were subjected to biochemical analysis.”
BackgroundMethod
Mechanisms And Functions Of Cell Death
Ellis, R. E., Yuan, J., & Horvitz, H. R. (1991) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.07.110191.003311 · Cited by 2,088
Parkinson's Disease
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391506 · Cited by 2,072
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Bergman, H., Wichmann, T., & Delong, M. (1990) · Science · doi:10.1126/science.2402638 · Cited by 2,003 · cited 1×
“Such was the case for the discovery of L-dopa, and more recently for the discovery that deep brain stimulation is an effective adjunctive treatment.(1,2) Despite these important advances, we remain unable to offer therapies that halt the progression of the disease, and in this crucial respect therapies for PD are as l…”
Background
Uneven Pattern of Dopamine Loss in the Striatum of Patients with Idiopathic Parkinson's Disease
Kish, S. J., Shannak, K. S., & Hornykiewicz, O. (1988) · New England Journal of Medicine · doi:10.1056/nejm198804073181402 · Cited by 1,945 · cited 1×
“ing on disease duration, although there has been 60 to 80% loss of SN dopamine neurons,(23,33) there has been a much more profound loss of striatal or putaminal dopaminergic markers.(26,28,29) It may still be argued that it is difficult to make comparisons in these data, due to dif-”
Background

Flagged first, then by citations

Show all 77 references

Research works printed but not linked: 4

Agid Y, 1987, Movement disorders 2, 166
Dodiya HB, 2009, The status of dopaminergic putaminal innervation in Parkinson's disease as a function of disease duration: relevance to trophic factor therapy, Abstr Soc Neurosci
Cheng HC, 2008, Akt/PKB inhibits retrograde axonal degeneration in the nigro‐striatal dopaminergic pathway in vivo, Abstr Soc Neurosci
Chen X, 2008, Restoration of the nigrostriatal dopaminergic pathway in mouse models of Parkinson's disease: effects of a constitutively active form of AKT, Abstr Soc Neurosci

Sorted by citations

Items 901–1,000 of 1,001

Characterization of Mice with Altered Dopamine Transporter and Vesicular Monoamine Transporter 2 Levels
Masoud, S. T. (2017) · TSpace (University of Toronto)
Quantitative T 1 mapping of the substantia nigra using phase-sensitive inversion recovery sequence at 3.0-T: a healthy volunteer study
Fujiwara, Y., Hirai, T., Ueda, T., Kumazoe, H., & Ito, S. (2020) · Acta Radiologica · doi:10.1177/0284185120920806
“For evaluating aging or pathological changes associated with the NM content of the SN, it may be simpler to interpret the T1 value obtained from PSIR images rather than that 246 Acta Radiologica 62(2)”
BackgroundMethod
Personality, stress and risk of Parkinson's disease
Sieurin, J. (2020) · Figshare
‘Capsula formativa’ para el reconocimiento de alteraciones y patrón de marcha en un paciente con la enfermedad de Parkinson
Castillo-Mariqueo, L., & Giménez‐Llort, L. (2020) · European Journal of Child Development Education and Psychopathology · doi:10.30552/ejpad.v8i1.132
Parkinson's Disease Detection with Ensemble Architectures based on ILSVRC ModelsPreprint
Mostafa, T. A., & Cheng, I. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2007.12496 · Cited by 4
“But these symptoms might not become apparent until 50 to 70% of neurons have been damaged [4], which is too late for”
Gene delivery for Parkinson's disease
Chmielarz, P., Panhelainen, A. E., Airavaara, M., & Domanskyi, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815946-0.00035-1
Molecular aspects of regeneration and neuroprotection in neurodegenerative diseases
Farooqui, A. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821711-5.00007-3
New insights underlying the early events of dopaminergic dysfunction in Parkinson’s DiseasePreprint
Cruz, H. L. D., Cruz, E. L. D., Zurhellen, C., York, H. T., Baun, J. A., Cruz, J. L. D., & Cruz, J. S. D. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.27.313957
WAVE-2 and Its Role in LRRK2 Mediated Neuroinflammation
Abdali, J. (2019) · doi:10.22215/etd/2019-13730
A New Kind of Pathogen – Prion diseases and amyloid fibrils
Gruschus, J. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85707-9.00002-2
Der Einfluss von humanem Wildtyp-Alpha-Synuclein und seinen Mutationen A30P und A53T auf das Neuritenwachstum primärer dopaminerger Mittelhirnneurone der Ratte
Haack, J. F. (2021) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8398
Electrophysiological Substrates of Cognition in the Basal Ganglia and Basal Forebrain
Al‐Ozzi, T. M. (2020) · TSpace (University of Toronto)
A Systematic Review of the Biological Processes Involved in Deep-Brain Stimulation for Parkinson's disease: A Focus on the Potential Disease-Modifying Effects
Sciancalepore, F., Remoli, G., Tariciotti, L., Sarti, G., Trentin, F., Riccardi, G., Lacorte, E., Corbo, M., Canevelli, M., Vanacore, N., et al. (2021) · OBM Neurobiology · doi:10.21926/obm.neurobiol.2102097
“It has been estimated that, by the time of onset of motor symptoms and subsequent diagnosis, the patients have already lost half of the striatal dopamine content, along with 30% of the nigral dopamine neurons [75].”
Background
Pharmacological Ablation of Astroglia in a Rat Model of Parkinson’s Disease
Groulx, C. (2021) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2021-14407
Image Prior Transfer and Ensemble Architectures for Parkinson’s Disease Detection
Mostafa, T. A., & Cheng, I. (2021) · Lecture notes in computer science · doi:10.1007/978-3-030-90439-5_5
Prediction Potential Analysis of Arabic Diacritics and Punctuation Marks in Online Handwriting: A New Marker for Parkinson’s Disease
Alae, A., Aouraghe, I., Khaissidi, G., Mrabti, M., Aboulem, G., & Belahsen, F. (2021) · Lecture notes in electrical engineering · doi:10.1007/978-981-33-6893-4_81
Die Souveränität der Asthetik. Georges Bataille an der Grenze der Wissenschaft
Ebeling, K. (2000) · Dialnet (Universidad de la Rioja)
Introducing age and sex dependent volumetric standards for basal nuclei using magnetic resonance imaging
Drake, T. C. (2021) · Queensland University of Technology · doi:10.5204/thesis.eprints.214321
Faculty Opinions recommendation of Mitofusin2 mutations disrupt axonal mitochondrial positioning and promote axon degeneration.
Hollenbeck, P. J. (2012) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.717951639.793456948
In vivo detection of substantia nigra and locus coeruleus volume loss in Parkinson’s disease using neuromelanin-sensitive MRI: Replication in two cohortsPreprint
Hwang, K., Langley, J. A., Tripathi, R., Hu, X. P., & Huddleston, D. E. (2022) · medRxiv · doi:10.1101/2022.02.23.22271356
NR4A2 (Nuclear Receptor Subfamily 4, Group A, Member 2)
Volpicelli, F., di Porzio, U., & Colucci-D’Amato, L. (2017) · Springer eBooks · doi:10.1007/978-3-319-67199-4_101617
NR4A2 (Nuclear Receptor subfamily 4, Group a, Member 2)
Volpicelli, F., di Porzio, U., & Colucci-D’Amato, L. (2016) · Springer eBooks · doi:10.1007/978-1-4614-6438-9_101617-1
Faculty Opinions recommendation of Synaptic changes in Parkinson's disease assessed with in-vivo imaging.
Caviness, J. N. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737231678.793570128
Lower lymphocyte count is associated with increased risk of Parkinson’s disease
Jensen, M. P., Jacobs, B. M., Dobson, R., Bandrés‐Ciga, S., Blauwendraat, C., Schrag, A. E., & Noyce, A. J. (2022) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2022-abn.306
Progress in the Detection of Cerebrospinal Fluid by Raman Spectroscopy
Zeng, T., Song, Y., Bian, H., Lin, T., Liu, Y., Deng, S., Liao, J., Mao, Z., & Chen, S. (2022) · Current Nanoscience · doi:10.2174/1573413718666220803141856
Axonal degeneration in the anterior insular cortex in Parkinson’s disease and Dementia with Lewy bodies: more than just an α-synuclein storyPreprint
Fathy, Y. Y., Jonkman, L. E., Bol, J. G. J. M., Timmermans, E., Jonker, A. J., Rozemüller, A. J. M., & van de Berg, W. D. J. (2022) · Research Square · doi:10.21203/rs.3.rs-1767866/v1
Pathology
Albin, R. L. (2022) · Oxford University Press eBooks · doi:10.1093/med/9780190843014.003.0003
Lebensstil und Parkinson-Risiko
Eschle, D. (2022) · Journal für Klinische Endokrinologie und Stoffwechsel · doi:10.1007/s41969-022-00174-z
Evaluation of a structured screening assessment to detect patients with isolated REM Sleep Behavior DisorderPreprint
Seger, A., Ophey, A., Heitzmann, W., Doppler, C. E. J., Lindner, M., Brune, C., Kickartz, J., Dafsari, H. S., Oertel, W. H., Fink, G. R., et al. (2022) · medRxiv · doi:10.1101/2022.10.23.22281409
Regulation des Autophagieproteins ULK1 im MPTP-Mausmodell des Morbus Parkinson
Balke, D. (2022) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9531
In Vivo Studies of various Antiparkinson’s agents: A Systematic Review
Vasava, N., & Gajera, V. (2022) · International Journal for Research in Applied Science and Engineering Technology · doi:10.22214/ijraset.2022.47603
Global Thresholding Technique for Basal Ganglia Segmentation from Positron Emission Tomography Images
Maalej, Z., Rejab, F. B., & Nouira, K. (2023) · Communications in computer and information science · doi:10.1007/978-3-031-27609-5_7
Diagnostic Biomarkers of Parkinson's Disease
Echchakery, M., Amane, M., Guennouni, M., Mohamed, O., Baz, S. E., Achbani, A., Midhat, L., Nassah, H., Aimrane, A., Draoui, A., et al. (2023) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-6684-5156-4.ch005
Einsatz KI-gestützter Diagnostik von Sprach- und Sprechstörungen bei neurodegenerativen Erkrankungen
Fischer, M., & Jäck, A. (2023) · Nervenheilkunde · doi:10.1055/a-2133-3482
Cellular, Behavioral, and Locomotor Effects of Oral Nicotine in Male Rats with Bilateral Lesions in the Ventrolateral Striatum Induced with 6-OHDA
Darol, E. S., Karson, A., Köktürk, S., & İşeri, P. (2023) · Clinical and Experimental Health Sciences · doi:10.33808/clinexphealthsci.1162013
Os impactos do programa fisioterapêutico domiciliar de reabilitação para pacientes com doença de Parkinson
de Souza, L. B. R., Vidal, A., Brandão, R. D. N. M., & dos Santos, E. C. S. (2023) · Research Society and Development · doi:10.33448/rsd-v12i14.44441
Identification of a circRNA-miRNA-mRNA interactome associated with Parkinson’s Disease progressionPreprint
Leier, A., & Shrestha, L. (2024) · Research Square · doi:10.21203/rs.3.rs-3859067/v1
Overcoming our shared challenge
Virameteekul, S., Maetzler, W., & Bhidayasiri, R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99494-1.00009-5
Gut-Brain Interplay and Cognitive Degeneration
Krishnamoorthy, K., Rajagopal, P., & Jayaraman, S. (2024) · Springer eBooks · doi:10.1007/978-981-99-8803-7_4
Neuroimaging study of the effects of transcranial static-magnetic-field stimulation on corticostriatal activity
Caballero‐Insaurriaga, J. (2024) · doi:10.20868/upm.thesis.81362
A Custom GPT Health Recommender System Informed by Causal Bayesian Networks and Authoritative Ontologies (Preprint)Preprint
Hu, H., & Kerschberg, L. (2024) · doi:10.2196/preprints.63297
Intrinsic Templates for Neurodegenerations Featuring Disease-Specific Axonal or Dendritic Vulnerability
Uchihara, T. (2024) · Oxford University Press eBooks · doi:10.1093/med/9780197676592.003.0005
A single Citrobacter rodentium infection in Pink1 knockout and wildtype mice leads to regional blood-brain-barrier perturbation and limited microglial activation without dopamine neuron axon terminal lossPreprint
Mukherjee, S., Grouza, V., Tchung, A., Even, A., Yaqubi, M., Tuznik, M., Cannon, T., Recinto, S. J., Gavino, C., Bourque, M.-J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.24.630165
A Study to Evaluate Various Machine Learning Approaches for Early Prediction of Neurodegenerative Diseases
Ahmed, S. S., Khatri, R., Garg, H., Sood, N., & Gupta, A. (2024) · International Conference on Computational Intelligence and Network Systems (CINS) · doi:10.1109/cins63881.2024.10862988
“A hallmark of Parkinson’s is the presence of Lewy bodies, abnormal aggregates of alpha-synuclein in affected neurons [29].”
Characterization of a novel mouse model of Dopamine Transporter Deficiency Syndrome and pharmacological therapeutic strategiesPreprint
Russo, E. E., Rezayof, A., Wallace, C. W., Williams, E. Q., Beerepoot, P., Milenkovic, M., Novalen, M., Blundell, A., Lipina, T. V., Locke, J. L., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.21.644417
Differentiating Treatment‐Resistant Depression With and Without Parkinsonism in the Elderly From a Psychiatric Perspective by 99mTc‐TRODAT‐1 SPECT Imaging
Su, T., Huang, C., Mao, W., Chiu, Y., Liu, R., & Chen, L. (2025) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.70102
Nanomaterial-based Neurotransmitter Sensors
Mohanan, M. P., Zarrin, P., Kivanc, A., Kulkarni, N. V., & Kurbanoğlu, S. (2025) · Royal Society of Chemistry eBooks · doi:10.1039/9781837675289-00327
HOPES AND HURDLES OF DENDRIMERS FOR THE TREATMENT OF PARKINSON’S DISEASE
AGGARWAL, K., Verma, S., RATHORE, A. S., & Parashar, T. (2025) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2025v18i6.54401
Computational Psychiatry and Eating Disorders
Sepúlveda, P., Aitsahalia, I. F., Dong, S., & Iigaya, K. (2025) · Oxford University Press eBooks · doi:10.1093/9780197675212.003.0006
Design, synthesis, investigation, and biological activity assessments of n -allyl-2-(benzylidene) hydrazine-1-carbothioamide derivatives as monoamine oxidase-b inhibitor agents
Ali, S. H., Osmani̇ye, D., Sağlık, B. N., Levent, S., Özkay, Y., & Kaplancıklı, Z. A. (2025) · Zeitschrift für Naturforschung C · doi:10.1515/znc-2025-0107
“…by motor abnormalities such as bradyki-nesia, sti ﬀ ness, and resting tremor [8], which were ﬁ rst described as the “ shaking palsy ” by Dr. James Parkinson in 1817 [9], which are all linked to striatal dopamine insu ﬃ ciency due to the loss of dopaminergic cells in the substantia nigra [10].”
Lewy pathology accumulates in swollen corticostriatal synapses in α-synucleinopathiesPreprint
Prigent, A., & Henderson, M. X. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.27.672679
“As reported in other studies 14,36 , pathology in the cingulate cortex is more severe than in frontal cortex.”
Influential
NATO3 protects dopaminergic neurons in mouse in vivo and human in vitro Parkinson’s disease modelsPreprint
Valencia-Alarcón, E. P., Duret, L. C., Kobayashi, E., Cattaneo, O., Schneider, B. L., & Nagoshi, E. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.10.681573
Rodent models for exploring the mechanisms contributing to Parkinson's disease pathophysiology
Allison, J., & Duty, S. (2025) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-443-21992-4.00003-8
Multiscale brain-wide mapping of α-synuclein-driven dopaminergic degeneration and white matter impairment in α-synucleinopathy micePreprint
Combes, B. F., Dong, S., Henrich, M. T., Rosenau, A. K., Karatsoli, M., Lu, J., Kollmorgen, S., Reisert, M., Wei, X., Zeng, T., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.05.692595
Optogenetic regulation of chloride ions in reactive astrocytes may mitigate Parkinson’s disease pathology
Lee, E. J., Yoon, H. H., & Jeon, S. R. (2025) · Scientific Reports · doi:10.1038/s41598-025-30935-0
“DA neurons of the SNpc are particularly susceptible to α-Syn pathologies, which lead to the cardinal motor symptoms of PD, such as resting tremor, bradykinesia, and rigidity, manifesting with little as a 30% loss of these neurons 1,12,21 .”
Additional file 8 of PARK7/DJ-1 deficiency impairs microglial activation in response to LPS-induced inflammation
Lind-Holm Mogensen, F., Sousa, C., Ameli, C., Badanjak, K., Pereira, S. L., Muller, A., Kaoma, T., Coowar, D., Scafidi, A., Poovathingal, S. K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26750087
Additional file 1 of Nonselective beta-adrenoceptor blocker use and risk of Parkinson’s disease: from multiple real-world evidence
Feng, Z., Zhao, Q., Wu, J., Yang, Y., Jia, X., Ma, J., Tang, H., Yuan, H., Yang, G., & Lu, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26639827
Additional file 9 of PARK7/DJ-1 deficiency impairs microglial activation in response to LPS-induced inflammation
Lind-Holm Mogensen, F., Sousa, C., Ameli, C., Badanjak, K., Pereira, S. L., Muller, A., Kaoma, T., Coowar, D., Scafidi, A., Poovathingal, S. K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26750090
Additional file 11 of PARK7/DJ-1 deficiency impairs microglial activation in response to LPS-induced inflammation
Lind-Holm Mogensen, F., Sousa, C., Ameli, C., Badanjak, K., Pereira, S. L., Muller, A., Kaoma, T., Coowar, D., Scafidi, A., Poovathingal, S. K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26750096
Additional file 1 of Reduced erythrocytic CHCHD2 mRNA is associated with brain pathology of Parkinson’s disease
Liu, X., Wang, Q., Yang, Y., Stewart, T., Shi, M., Soltys, D., Liu, G., Thorland, E., Cilento, E. M., Hou, Y., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14183759
Additional file 2 of PARK7/DJ-1 deficiency impairs microglial activation in response to LPS-induced inflammation
Lind-Holm Mogensen, F., Sousa, C., Ameli, C., Badanjak, K., Pereira, S. L., Muller, A., Kaoma, T., Coowar, D., Scafidi, A., Poovathingal, S. K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26750069
Additional file 10 of PARK7/DJ-1 deficiency impairs microglial activation in response to LPS-induced inflammation
Lind-Holm Mogensen, F., Sousa, C., Ameli, C., Badanjak, K., Pereira, S. L., Muller, A., Kaoma, T., Coowar, D., Scafidi, A., Poovathingal, S. K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26750093
Additional file 6 of PARK7/DJ-1 deficiency impairs microglial activation in response to LPS-induced inflammation
Lind-Holm Mogensen, F., Sousa, C., Ameli, C., Badanjak, K., Pereira, S. L., Muller, A., Kaoma, T., Coowar, D., Scafidi, A., Poovathingal, S. K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26750081
Additional file 5 of PARK7/DJ-1 deficiency impairs microglial activation in response to LPS-induced inflammation
Lind-Holm Mogensen, F., Sousa, C., Ameli, C., Badanjak, K., Pereira, S. L., Muller, A., Kaoma, T., Coowar, D., Scafidi, A., Poovathingal, S. K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26750078
Additional file 3 of PARK7/DJ-1 deficiency impairs microglial activation in response to LPS-induced inflammation
Lind-Holm Mogensen, F., Sousa, C., Ameli, C., Badanjak, K., Pereira, S. L., Muller, A., Kaoma, T., Coowar, D., Scafidi, A., Poovathingal, S. K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26750072
Additional file 1 of PARK7/DJ-1 deficiency impairs microglial activation in response to LPS-induced inflammation
Lind-Holm Mogensen, F., Sousa, C., Ameli, C., Badanjak, K., Pereira, S. L., Muller, A., Kaoma, T., Coowar, D., Scafidi, A., Poovathingal, S. K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26750066
Additional file 7 of PARK7/DJ-1 deficiency impairs microglial activation in response to LPS-induced inflammation
Lind-Holm Mogensen, F., Sousa, C., Ameli, C., Badanjak, K., Pereira, S. L., Muller, A., Kaoma, T., Coowar, D., Scafidi, A., Poovathingal, S. K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26750084
Additional file 4 of PARK7/DJ-1 deficiency impairs microglial activation in response to LPS-induced inflammation
Lind-Holm Mogensen, F., Sousa, C., Ameli, C., Badanjak, K., Pereira, S. L., Muller, A., Kaoma, T., Coowar, D., Scafidi, A., Poovathingal, S. K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26750075
Magnetic Resonance Imaging and Dopamine Transporter Imaging in Parkinson’s Disease
Joza, S., & Ba, F. (2025) · Springer eBooks · doi:10.1007/978-3-031-95878-6_2
Striatal dopamine synthesis capacity in Parkinson’s disease: Effects of age, sex, and body mass index in a large [18F]fluorodopa PET cohort
Malén, T., Tuisku, J., Bucci, M., Santavirta, S., Kaasinen, V., Kaasalainen, S., Isojärvi, J., Hietala, J., Rinne, J. O., & Nummenmaa, L. (2025) · bioRxiv · doi:10.1016/j.nicl.2026.103944
“Motor symptoms are estimated to occur with approximately 30% (while also higher estimations exist) degeneration of the dopamine nerves in substantia nigra (Cheng et al., 2010).”
The Neuroprotective Role of Resveratrol
Fatimi, H. E., Ndayambaje, M., Skaou, A., & El‐Mansoury, B. (2026) · IGI Global eBooks · doi:10.4018/979-8-3373-1365-8.ch006
Parkinson’s disease biomarkers: bridging the gap between diagnosis and treatment
Chakkarwar, V. A., & Kulkarni, Y. A. (2026) · Behavioural Brain Research · doi:10.1016/j.bbr.2026.116120
Détection et caractérisation de l'α-synucléine dans le système nerveux entérique en conditions physiologiques et dans la maladie de Parkinson
Corbillé, A.-G. (2016) · theses.fr (ABES) · doi:10.70675/b7f90304z205dz41cczbcf0z0e8903131ad2
Etude physiopathologique de la diffusion de la maladie de parkinson au système nerveux autonome
Leclair‐Visonneau, L. (2017) · theses.fr (ABES) · doi:10.70675/6537e18cze1c8z4bd8zad04z73a63a9ae4fe
Development of Inhibitors of Amyloid Fibril Propagation
Bendifallah, M. (2019) · theses.fr (ABES) · doi:10.70675/a872e5bdzc153z41f4z9472z725fd78aab48
Study of the pair Netrin-1/DCC in Parkinson's diseas
Jasmin, M. (2018) · theses.fr (ABES) · doi:10.70675/a5c587d5zfa52z4a76zb257z2e99fdc6fd11
Étude génétique et corrélation génotype-phénotype de la maladie de Parkinson dans la population tunisienne
Romdhan, S. B. (2019) · theses.fr (ABES) · doi:10.70675/6735d8bdz3448z4836z8b6dzffcd8f2bd2da
Towards the integration of body-worn sensors in the management of Parkinson’s disease : perspectives on new paradigms of follow-up
Virbel-Fleischman, C. (2021) · theses.fr (ABES) · doi:10.70675/21583008z772az4c86z822dza5cca46513d5
Identification de nouvelles sondes moléculaires contre des biomarqueurs des maladies neurodégénératives
Bouvier‐Müller, A. (2020) · theses.fr (ABES) · doi:10.70675/2097d129z95aaz45f5zbf91z199fddefb42c
Physiopathologie de l'hétérogénéité phénotypique et pronostique de la maladie de Parkinson : études de cohortes et imagerie multimodale in vivo
Prange, S. (2020) · theses.fr (ABES) · doi:10.70675/0ff04d40z70a8z46b4zb7c8z2271c944c9bd
Nigral Neuromelanin and Iron Content characterizing Parkinson's Disease and REM Sleep Behavior Disorder : A Multimodal MRI Study using Deep Learning
Gaurav, R. (2021) · theses.fr (ABES) · doi:10.70675/da1b9357z3d8cz4fe2z84f7ze7075e9af0d6
Interaction entre autophagie et exosomes au niveau synaptique dans la maladie de Parkinson
Sanchez-Mirasierra, I. (2023) · theses.fr (ABES) · doi:10.70675/7104d6d5z945ez494eza917zda9e6be1eea6
Étude de la physiopathologie de l'épilepsie du lobe temporal : analyse détaillée de la myélinisation des interneurones à parvalbumine et des réactions gliales
Vigier, A. (2023) · theses.fr (ABES) · doi:10.70675/65eec3acz4916z460cza447zbbae94dd481e
Evaluation of the impact of microbiome-based therapies on non-motor symptoms in Parkinson's disease: A systematic review and meta-analysis
Mojica, E. P., Aranis, N., Ribeiro, J. V., Soto-Rodríguez, A., & Fregni, F. (2026) · Gut Microbiology · doi:10.1016/j.gutmic.2026.100007
Diffusion Magnetic Resonance Imaging of Cortical Microstructure Differs in Nonmanifest and Manifest Genetic Parkinson's Disease
Torso, M., Tzaferou, D., Valotti, M., Hardwidge, J., Hardingham, I., Koychev, I. G., Guo, Q., Comley, R. A., Chance, S. A., & Ridgway, G. R. (2026) · Movement Disorders · doi:10.1002/mds.70298
“58,59 Signi ﬁ cant reductions in ParlPD values across several cortical regions, particularly in GBA1 carriers, suggest a pathogenic role for α -syn in cortical deafferentation, consistent with animal evidence showing layer-speci ﬁ c reduction of serotonergic input to the prefrontal cortex layers II…”
Beyond the brain: a multisystem review of pathogenesis, comorbidity, and therapeutic progress in sporadic Parkinson’s disease
Li, Y., Guo, L., Yu, X., & Peng, C. (2026) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2025.31
Nicotine protects astrocytes expressing alpha-synuclein against aminochrome cytotoxicity: Implications for Parkinson’s diseasePreprint
Soares, É. N., Bartolomeo, C. S., Nicoliche, T., Lima, I. S., de Oliveira, L. M. G., Ferrolho, G. D. J., Oliveira, R. B., Stilhano, R. S., Costa, S. L., Tizabi, Y., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9410157/v1
“As the substantia nigra neurons are the main producers of dopamine in the brain (Cheng et al. 2010), the direct consequence of the neurodegeneration of this brain’s area results in the onset of the classic motor symptoms, such as dyskinesia, muscle rigidity, postural instability, and tremors at…”
Identification of genes associated with smell dysfunction in Parkinson’s disease
Ali, M. Z., Kiran, M., & Dholaniya, P. S. (2026) · Clinical Parkinsonism & Related Disorders · doi:10.1016/j.prdoa.2026.100453
“Typically, these motor indicators emerge only after significant neuronal degeneration, with nearly half of the brain ’ s dopamine-producing neurons already lost, irreversibly reducing dopamine levels [1,2].”
Long-term low-dose nanoplastic exposure induces neurotoxicity with oxidative brain damage
Ying, P., Bao, Q., Jiang, Y., Chen, T., Li, Z., Sun, Y., & zhang, L. (2026) · Food and Chemical Toxicology · doi:10.1016/j.fct.2026.116173 · Cited by 1
The autophagy core protein Atg18 regulates exosome release and rescues pathogenic dysfunction associated to Parkinson Sac domain mutation in SynaptojaninPreprint
Sanchez-Mirasierra, I., Hernández-Díaz, S., Barry-Carroll, L., Marti, A. A., Ghimire, S., Delpech, J.-C., & Soukup, S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.26.727892
Food-derived bioactive peptides against α-synuclein aggregation in Parkinson's disease
Padhy, P. K., & Udenigwe, C. C. (2026) · Food Bioscience · doi:10.1016/j.fbio.2026.109247
Mitochondria-targeted delivery of bromocriptine via cerium vanadate nanocarriers for Parkinson’s disease
Mishra, K., Tiwari, A. K., Amrutha, K. A., Dadge, S. D., Rana, R., Tripathi, S., Verma, P., Vale, A. M., Silva, A., Fiadeiro, M. B., et al. (2026) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2026.115151
Development of a rapid and simple Xeno Nucleic Acid (XNA) sensor-based microRNA detection platform for Parkinson’s disease diagnostics
Byun, M. Y., Ryu, M. Y., Chung, S. J., Lee, B., Oh, J. R., Woo, J. K., Shin, J. Y., Han, M. K., Bang, O. Y., Kim, Y. W., et al. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04707-5
Peripheral manifestations of nigrostriatal neurodegeneration in Parkinson’s disease
Joseph, J. H. M., & Kandasamy, M. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.06.003
A single Citrobacter rodentium infection in Pink1 knockout and wild-type mice leads to regional blood-brain-barrier perturbation and limited microglial activation without dopamine neuron axon terminal loss
Mukherjee, S., Grouza, V., Tchung, A., Even, A., Yaqubi, M., Tuznik, M., Cannon, T., Recinto, S. J., Gavino, C., Bourque, M.-J., et al. (2026) · PLoS Pathogens · doi:10.1371/journal.ppat.1014315 · Cited by 1
“The axonal domain of these neurons has been hypothesized to be particularly vulnerable to inflammatory and other neurotoxic signals [17–19].”
The conundrum of alpha-synuclein antibody failures in Parkinson’s disease: a narrative review of mechanisms and alternative metabolic hypotheses
Bougea, A. M. (2026) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864261465665
“24,91 Because of this extremely subtle and continuous decline, clinical measures like the MDS-UPDRS are unlikely to detect neuroprotective effects from monoclonal antibodies over a standard trial period.”
Substantia Nigra Susceptibility‐To‐Volume Ratio Derived From QSM as a Marker for Discrimination of Progressive Supranuclear Palsy From Parkinson's Disease and Multiple System Atrophy
Candan, H. E., Jo, S., Myratgeldyyev, N., Tessema, A. W., Lee, H., Lee, J., Lee, H., Lee, G. Y., Suh, C. H., Ryu, J., et al. (2026) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.70459
Network of weakly coupled nonlinear reentrant polysynaptic oscillators
Montgomery, E. B. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45819-4.00008-4
The aging brain that doesn’t fail: how neural resilience masks neurodegeneration
Eisen, A., Durham, H. D., & Pioro, E. (2026) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2026.2705693 · Cited by 1
Effectiveness of mixed reality-based rehabilitation on motor function in Parkinson’s disease. A two-arm randomized trial
Papamichael, E., Michailidou, C., & Giannaki, C. D. (2026) · Digital Health · doi:10.1177/20552076261473784

Authors: Cheng, H., Ulane, C. M., & Burke, R. E.
Affiliations: Columbia University Irving Medical Center (US)
Corresponding author: Burke, Robert E.
ORCID: Burke, Robert E.
Venue: Annals of Neurology
Publisher: Wiley
Published: 2010-05-26
Volume: 67
Issue: 6
Pages: 715-725
ISSN: 0364-5134 (ISSN-L)
1531-8249
DOI: 10.1002/ana.21995
PMC: PMC2918373
OpenAlex: W1967659552
Cited by: 1,012
References: 77
Citations by year: 2026: 56 · 2025: 74 · 2024: 101 · 2023: 92 · 2022: 108 · 2021: 109 · 2020: 100 · 2019: 82 · 2018: 67 · 2017: 59 · 2016: 35 · 2015: 36 · 2014: 24 · 2013: 22 · 2012: 23
FWCI: 12.98
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Annals of Neurology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institute of Neurological Disorders and Stroke (NS26836, P50NS038370, R56NS026836, NS38370, R01NS026836)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
Keywords: Parkinson's disease, axonal degeneration, disease progression, axonal injury, programmed cell death, therapeutic target, pathogenesis, axon terminals
MeSH terms: Axons, Humans, Neurobiology, Neurons, Parkinson Disease, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Clinical progression in Parkinson disease and the neurobiology of axons

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks